Cargando…

Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors

INTRODUCTION: Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptom (LUTS) development in men [1]. The intensity of the symptoms may vary from mild to severe, significantly affecting the quality of life. Erectile dysfunction (ED) is one of the most challenging is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolontarev, Konstantin, Govorov, Alexander, Kasyan, George, Priymak, Diana, Pushkar, Dmitry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Polish Urological Association 2016
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260456/ https://www.ncbi.nlm.nih.gov/pubmed/28127458 http://dx.doi.org/10.5173/ceju.2016.879

Ejemplares similares

Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia
por: Govorov, Alexander, et al.
Publicado: (2014)

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH
por: Gacci, M., et al.
Publicado: (2013)

Extended robotic salvage lymphadenectomy in patients with ‘node-only’ prostate cancer recurrence: initial experience
por: Kolontarev, Konstantin, et al.
Publicado: (2018)

Robot-assisted laparoscopic ureteral reconstruction: а systematic review of literature
por: Kolontarev, Konstantin, et al.
Publicado: (2018)

Robotic surgery in ureteral reconstruction
por: Kolontarev, Konstantin, et al.
Publicado: (2014)

Current consensus and controversies on male LUTS/BPH (part one)
por: Foo, Keong Tatt
Publicado: (2017)

Current consensus and controversies on male LUTS/BPH (part two)
por: Foo, Keong Tatt
Publicado: (2018)

Moving beyond BPH – A contemporary update on male LUTS
por: Chapple, Christopher R.
Publicado: (2019)

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED
por: Sebastianelli, A., et al.
Publicado: (2020)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH
por: Gupta, Saurabh
Publicado: (2014)

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH
por: Roehrborn, C G, et al.
Publicado: (2011)

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH
por: De Nunzio, Cosimo, et al.
Publicado: (2022)

Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
por: Manohar, Chikka Moga Siddaiah, et al.
Publicado: (2017)

Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
por: Alcaraz, Antonio, et al.
Publicado: (2021)

LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations
por: De Nunzio, Cosimo, et al.
Publicado: (2021)

Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH
por: Wang, Xing-Huan, et al.
Publicado: (2015)

Detection of Prostatic Inflammation From Peripheral Lymphocyte Count and Free/Total PSA Ratio in Men With LUTS/BPH
por: Liao, Xinyang, et al.
Publicado: (2020)

Bulking agents for urinary incontinence: what, when and where?
por: Kasyan, George, et al.
Publicado: (2015)

AB201. Two birds with one stone: α-blocker therapy on LUTS/BPH in men concomitant with mild hypertension
por: Xiao, Hengjun, et al.
Publicado: (2016)

WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
por: Kirschner-Hermanns, Ruth, et al.
Publicado: (2019)

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone
por: Boeri, Luca, et al.
Publicado: (2017)

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands
por: Drake, Marcus J., et al.
Publicado: (2017)

Use of Martius flap in the complex female urethral surgery
por: Kasyan, George, et al.
Publicado: (2014)

Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression
por: D’Agate, Salvatore, et al.
Publicado: (2020)

Cluster analysis of men undergoing surgery for BPH/LUTS reveals prominent roles of both bladder outlet obstruction and diminished bladder contractility
por: Schneider, Andrew J., et al.
Publicado: (2021)

Evidence of heat-resistant microorganisms with a special emphasis on filamentous Actinomycetes in hyper-arid soils of Gandom Beryan area, Lut Desert, Iran
por: Mazkour, Somaye, et al.
Publicado: (2017)

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH
por: D’Agate, Salvatore, et al.
Publicado: (2019)

Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis with Hunner’s lesions or glomerulations: systematic review and meta-analysis
por: Grigoryan, Bagrat, et al.
Publicado: (2022)

Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study
por: Zhang, Weiyu, et al.
Publicado: (2019)

Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study
por: Alcaraz, Antonio, et al.
Publicado: (2020)

The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
por: Woo, Henry H., et al.
Publicado: (2022)

Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs
por: Sun, Xifeng, et al.
Publicado: (2018)

Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
por: Cindolo, Luca, et al.
Publicado: (2015)

Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study
por: Alcaraz, Antonio, et al.
Publicado: (2022)

Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial
por: Pushkar, Dmitry, et al.
Publicado: (2018)

Urogenital disorders after pelvic ring injuries
por: Ter–Grigorian, Atom A., et al.
Publicado: (2013)

Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
por: Kasyan, George, et al.
Publicado: (2021)

Relationship among diet habit and lower urinary tract symptoms and sexual function in outpatient-based males with LUTS/BPH: a multiregional and cross-sectional study in China
por: Chen, Yuke, et al.
Publicado: (2016)

Making shared decisions with older men selecting treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH): a pilot randomized trial
por: Ngu, Haidee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2fag36hi642el51idni8u6vjve